Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

Introduction: A proof-of-concept study was designed to evaluate the antiviral efficacy, safety and tolerability of a two-drug regimen with dolutegravir 50 mg once daily (QD) plus lamivudine 300 mg once daily as initial highly active antiretroviral therapy (HAART) among antiretroviral (ARV)-naive pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cahn, Pedro, Rolón, María José, Figueroa, María Inés, Gun, Ana, Patterson, Patricia, Sued, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515053/
https://www.ncbi.nlm.nih.gov/pubmed/28537061
http://dx.doi.org/10.7448/IAS.20.01.21678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515053/
https://www.ncbi.nlm.nih.gov/pubmed/28537061
http://dx.doi.org/10.7448/IAS.20.01.21678

Ejemplares similares